MAZEMaze Therapeutics, Inc.
$27.11+18% 1Y
$27.11
$22.4052 weeks$51.83
The financials
Maze Therapeutics, Inc. by the numbers
Maze Therapeutics, Inc. (MAZE) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $45M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$48M | −$36M | n/a |
| Net income | −$45M | −$34M | n/a |
| Diluted EPS | −$0.76 | −$0.77 | n/a |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $0.00 (-100%)
Segment Latestquarter on quarteryear on year
- United States$0.00$0.00quarter on quarter -100%year on year n/a-100%n/a
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry